T细胞受体
嵌合抗原受体
转基因
转录激活物样效应核酸酶
生物
基因组编辑
过继性细胞移植
T细胞
清脆的
睡美人转座系统
病毒载体
细胞生物学
遗传学
转座因子
基因
基因组
免疫系统
重组DNA
作者
Inan Edes,Julian Clauss,Rainer Stahn,Alberto Sada Japp,Felix K.M. Lorenz
标识
DOI:10.1007/978-1-0716-2441-8_5
摘要
AbstractThe efficient expression of T-cell receptors (TCRs) or chimeric antigen receptors (CARs) in primary human T cells is crucial for preclinical testing of receptor properties for adoptive T-cell therapies. Multiple streams of technological platforms have been developed in the recent decades to genetically modify primary T cells including nonviral platforms such as transposon-based systems (PiggyBac, Sleeping Beauty), TALENs, or CRISPR-Cas9). The production of CAR- or TCR-encoding retroviral vectors, however, is still the most commonly used technique both in preclinical as well as in clinical settings.In this chapter we describe a comprehensive 12-day protocol for (a) generating high-titered gamma-retroviral vector particles containing the transgene of interest (e.g., TCR , CAR ), (b) the isolation, activation and rapid expansion of primary T cells and (c) the stable genetic engineering of these T cells with the transgene for subsequent characterization.Key wordsPrimary human T cellsT-cell receptorChimeric antigen receptorGamma-retrovirusRetroviral vectorTransfectionTransductionGenetic engineering
科研通智能强力驱动
Strongly Powered by AbleSci AI